{"count": 3, "results": [{"_id": "38421924", "pmid": 38421924, "title": "Predicting Conversion to Insulin Sensitivity With Metformin: A Promising Tool for Clinicians in Addressing Insulin Resistance and Improving Outcomes in Patients With Treatment Resistant Bipolar Depression.", "journal": "J Clin Psychopharmacol", "authors": ["Gannon JM", "Sanchez M", "Lines K", "Cairns K", "Reardon C", "Chengappa KNR", "Calkin CV"], "date": "2024-03-01T00:00:00Z", "doi": "10.1097/JCP.0000000000001818", "meta_date_publication": "2024 Mar-Apr 01", "meta_volume": "44", "meta_issue": "2", "meta_pages": "157-160", "score": 50260.836, "text_hl": "Furthermore, these data suggest early intervention with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ at lower BMI, and HOMA-@DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@ would likely reverse @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@ in @<m>DISEASE_Depressive_Disorder_Treatment_Resistant</m> @DISEASE_MESH:D061218 @@@TRBD@@@.", "citations": {"NLM": "Gannon JM, Sanchez M, Lines K, Cairns K, Reardon C, Chengappa KNR, Calkin CV. Predicting Conversion to Insulin Sensitivity With Metformin: A Promising Tool for Clinicians in Addressing Insulin Resistance and Improving Outcomes in Patients With Treatment Resistant Bipolar Depression. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):157-160. PMID: 38421924", "BibTeX": "@article{38421924, title={Predicting Conversion to Insulin Sensitivity With Metformin: A Promising Tool for Clinicians in Addressing Insulin Resistance and Improving Outcomes in Patients With Treatment Resistant Bipolar Depression.}, author={Gannon JM and Sanchez M and Lines K and Cairns K and Reardon C and Chengappa KNR and Calkin CV}, journal={J Clin Psychopharmacol}, volume={44}, number={2}, pages={157-160}}"}}, {"_id": "35120288", "pmid": 35120288, "title": "Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial.", "journal": "J Clin Psychiatry", "authors": ["Calkin CV", "Chengappa KNR", "Cairns K", "Cookey J", "Gannon J", "Alda M", "O'Donovan C", "Reardon C", "Sanches M", "Růzicková M"], "date": "2022-02-01T00:00:00Z", "doi": "10.4088/JCP.21m14022", "meta_date_publication": "2022 Feb 1", "meta_volume": "83", "meta_issue": "2", "meta_pages": "", "score": 50260.277, "text_hl": "Further characterization of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ converters with @<m>DISEASE_Depressive_Disorder_Treatment_Resistant</m> @DISEASE_MESH:D061218 @@@TRBD@@@ will prove informative. ", "citations": {"NLM": "Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, O'Donovan C, Reardon C, Sanches M, Růzicková M. Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial. J Clin Psychiatry. 2022 Feb 1;83(2):. PMID: 35120288", "BibTeX": "@article{35120288, title={Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial.}, author={Calkin CV and Chengappa KNR and Cairns K and Cookey J and Gannon J and Alda M and O'Donovan C and Reardon C and Sanches M and Růzicková M}, journal={J Clin Psychiatry}, volume={83}, number={2}}"}}, {"_id": "28276972", "pmid": 28276972, "title": "Pharmacotherapy of 'treatment resistant' type 2 diabetes.", "journal": "Expert Opin Pharmacother", "authors": ["Scheen AJ"], "date": "2017-04-01T00:00:00Z", "doi": "10.1080/14656566.2017.1297424", "meta_date_publication": "2017 Apr", "meta_volume": "18", "meta_issue": "5", "meta_pages": "503-515", "score": 50049.69, "text_hl": "Expert opinion: Before considering intensifying the pharmacotherapy of a @SPECIES_9606 @@@patient@@@ with poorly controlled @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@, it is important to verify treatment adherence, target @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@ and consider various non pharmacological improvement quality interventions. If @<m>DISEASE_Depressive_Disorder_Treatment_Resistant</m> @DISEASE_MESH:D061218 @@@treatment resistant diabetes@@@ is defined as not achieving glycated haemoglobin target despite oral triple therapy with a third @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@-lowering agent added to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@-@CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ dual treatment, the combination of a @GENE_DPP4 @GENE_1803 @@@dipeptidyl peptidase-4@@@ (@GENE_DPP4 @GENE_1803 @@@DPP-4@@@) inhibitor and a @GENE_SLC5A2 @GENE_6524 @@@sodium glucose cotransporter type 2@@@ (@GENE_SLC5A2 @GENE_6524 @@@SGLT2@@@) inhibitor may offer new opportunities before considering injectable therapies. ", "citations": {"NLM": "Scheen AJ. Pharmacotherapy of 'treatment resistant' type 2 diabetes. Expert Opin Pharmacother. 2017 Apr;18(5):503-515. PMID: 28276972", "BibTeX": "@article{28276972, title={Pharmacotherapy of 'treatment resistant' type 2 diabetes.}, author={Scheen AJ}, journal={Expert Opin Pharmacother}, volume={18}, number={5}, pages={503-515}}"}}]}